key: cord-0924797-0p9oahkc authors: Pavoni, Vittorio; Gianesello, Lara; Pazzi, Maddalena; Stera, Caterina; Meconi, Tommaso; Frigieri, Francesca Covani title: Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action date: 2020-09-13 journal: Thromb Res DOI: 10.1016/j.thromres.2020.09.013 sha: 1c47199e4619457904fee1f1359d55e8886e22f8 doc_id: 924797 cord_uid: 0p9oahkc BACKGROUND: Critically ill COVID-19 patients have a clear pattern of inflammation and hypercoagulable state. The main aim of the study was to evaluate the outcome of severe COVID-19 patients basing on prothrombotic risk factors (i.e. D-dimer). We also evaluated the impact of different doses of low molecular weight heparin (LMWH) on incidence of major bleedings. METHODS: The data of forty-two patients admitted to the Intensive Care Unit (ICU) were retrospectively analyzed. On ICU admission, patients with D-dimer < 3000 ng/mL (Group 1) received enoxaparin 4000 UI (6000 UI, if body mass index >35) subcutaneously b.i.d. and patients with D-dimer ≥ 3000 ng/mL (Group 2) received enoxaparin 100 UI/kg every 12 h. Aspirin was administered to all patients once a day. RESULTS: Both groups presented a high incidence of perivascular thrombosis (40% in Group 1 and 30% in Group 2). Patients of Group 2 suffered a higher incidence of venous thromboembolism (VTE) than Group 1 (65% vs 13.6%, p = 0.001). One patient (4.5%) of Group 1 and three patients (15%) of Group 2 suffered from minor bleeding; no patient had major bleeding. Group 2 had a longer ICU and hospital stay than Group 1 (11.8 ± 5.1 vs 9.0 ± 4.8 and 30 ± 4.9 vs 21 ± 2.3, p < 0.05, respectively) as well as increased ICU mortality (25% vs 9.1%). CONCLUSIONS: More severe critically ill COVID-19 patients have a high incidence of VTE and worse outcome, despite the use of heparin at the therapeutic dose. However, the use of heparin did not increase the incidence of bleeding complications. Coronavirus disease 2019 (COVID -19) had been suggested to be caused by upregulation of pro-inflammatory cytokines [1] . Protein mediators of inflammation, including Tumor Necrosis Factor (TNF), Interleukin 6 (IL-6) and Interleukin 8 (IL-8), promote thrombosis. Thrombin can trigger an inflammatory response in endothelial cells, platelets, and smooth muscle cells. In the presence of thrombosis, circulating IL-6 rises and increases liver production of fibrinogen, plasminogen-activator inhibitor, and C-reactive protein; in the same way, thrombin stimulates multiple pro-inflammatory cytokines in human vascular smooth muscle cells [2] . Clinical evidence and emerging data from radiological examinations indicate a high incidence of thrombotic complications in critically ill and non-critically ill COVID-19 patients [3] [4] [5] . Some studies [6, 7] have suggested that anticoagulant therapy with heparin reduces the inflammatory response because thrombosis and inflammation are closely interconnected. Recent data in an Italian population [8] showed that an increase of thromboprophylaxis with LMWH 6.000 b.i.d (8.000 b.i.d if body mass index >35) plus clopidogrel loading dose 300 + 75 mg/day (if platelet count >400.000 cells/µL), was associated with a significant time-related decrease of fibrinogen levels, D-dimer and pro-coagulant profile. Tang et al [9] found that low molecular weight heparin (LMWH) or unfractionated heparin (UFH) at prophylactic doses was associated with a reduced 28-day mortality in COVID-19 patients with sepsis induced coagulopathy (SIC) score≥4 or D-dimer levels ≥6 fold the upper limit of normal. In 2016, the International Guidelines for management of sepsis and septic shock [10] , recommended pharmacologic thromboprophylaxis with LMWH in hospitalized septic patients, while the guidelines on the management of critically ill patients with coronavirus disease 2019 [11] do not mention thromboembolic prophylaxis. Recently [12] , a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of venous thromboembolism (VTE) associated with COVID-19; the authors recommend pharmacological prevention with LMWH (i.e. 4.000 IU of enoxaparin or 2.850 IU of nadroparin once per day and adjusted dose for overweight or obese patients) as first line treatment in severe or critically ill COVID-19 patients. On the same line were the recommendations of the World Health Organization [13] . Currently, given establish the incidence of derangement of the coagulation process and complications according to the severity of illness and the anticoagulant therapy. A single-centre, retrospective, observational study was done in the Anesthesia and Intensive Care Unit (ICU), Santa Maria Annunziata Hospital (Bagno a Ripoli, Tuscany, Italy), which is one of the designated hospitals in the region of Tuscany to treat patients with COVID-19 pneumonia. Forty-two adult patients (≥18 years old) admitted to the ICU because of COVID-19 pneumonia were retrospectively evaluated. Patients at time of admission already on vitamin K antagonists (AVK), direct oral anticoagulants (DOAC), or antiplatelet treatment with known bleeding diathesis or coagulation disorders were not included in the present study. The diagnosis of severe COVID-19 pneumonia was according to World Health Organization (WHO) [13] interim guidance and was confirmed by two consecutive qualitative Reverse Demographic and clinical information were collected, including age, gender, body mass index (BMI), preexisting conditions (diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, obesity), onset of symptom to hospital admission and to ICU admission, Sequential Organ Failure Assessment (SOFA) on ICU admission, PaO 2 /FiO 2 on ICU admission, need for non-invasive ventilation or mechanical ventilation, total length of ICU and hospital stay, and ICU and hospital mortality. The Sepsis Induced Coagulopathy (SIC) score system including PT, platelet count and SOFA was calculated and a SIC criteria total score ≥4 was considered, as suggested by International Society of Thrombosis and Haemostasis (ISTH) [14] . Based on previous studies [9;15] that found a different outcome for different D-dimer values, patients were divided into two groups upon admission to the ICU: a first group with D-dimer < 3.000 ng/mL that received intermediate dose (Group 1) (enoxaparin 4.000 UI or 6.000 UI, if body mass index >35, subcutaneously every 12 hours) and a second group with a D-dimer≥ J o u r n a l P r e -p r o o f Journal Pre-proof 3 .000 ng/mL that received a therapeutic dose (Group 2) (enoxaparin100 UI/Kg b.i.d). Aspirin (100 mg) was administered to all patients once a day. During the study period, as required by the internal ICU protocol, in-patients with acute kidney injury (AKI), according to KDIGO definitions [16] , the anti-Xa monitoring was made. A therapeutic level of 0.5-0.7 IU/mL of anti-Xa activity was considered [17] . Moreover, in case of a decrease in platelet count at >50% of the basal value, the 4T score was used for diagnosis of heparin-induced thrombocytopenia (HIT) [18] ; for each patient, the Padua prediction score was also calculated [19] . A cumulative score of 4 or more was defined as a high risk of VTE. All patients underwent a therapeutic protocol, shared by a multidisciplinary team composed of infectious disease specialists and pharmacologists, on the day of the hospital admission and throughout the hospital stay. The incidence of thrombotic and bleeding events was assessed. If the patient was not transportable a transthoracic echocardiography was performed to identify indirect cardiac signs of pulmonary embolism as well as pulmonary arterial hypertension. According to the Control of Anticoagulation Subcommittee [20] , major bleeding events were based on the presence of symptomatic bleeding in a critical area or organ, such as intracranial, intraarticular, intraabdominal or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or leading to transfusion of two or more units of whole blood or red cells. Non-major bleeding was defined as unexpected haematoma >25 J o u r n a l P r e -p r o o f Journal Pre-proof cm 2 , spontaneous nose-mouth bleeding >5 minutes, macroscopic hematuria, airway bleeding and hematemesis [21] . The results were expressed as mean ± standard deviation or number (percentage), wherever appropriate. Normally distributed data were compared by Student's t-tests. Categorical variables were compared using the chi-squared test. A p value of < 0.05 was considered statistically significant. SPSS software version 25.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Of the 42 patients that were included, 32 (76.2%) had a Padua risk score more than 4 and 10 (23.8%) had a risk score of 4. Ninety-two percent of patients received antivirals, 94% were prescribed an antibiotic therapy. Tocilizumab was administered to 25% of the patients, while corticosteroids were given to 45% of the cases. Table 1 . Among the laboratory parameters only IL-6 was statistically significantly higher in Group 2 than Group 1 (157.6 ± 83.7 vs 27 ± 6.9, p=0.046). None of patients met SIC and HIT criteria. No patients suffered of AKI. Major laboratory markers are shown in Table 2 . One patient (4.5%) of Group 1 and 3 (15%) of Group 2 suffered from minor bleedings; two patients of Group 2 had airway bleedings and one patient of Group 1 and one of Group 2 presented macroscopic hematuria. No patients suffered major bleedings. Both groups presented a high incidence of catheter-related venous thrombosis (40% in Group 1 and 30% in Group 2). Ten thrombosis cases (23.8%) were associated with an internal jugular catheter and one (2.4%) with a subclavian catheter; four incidences of thrombosis (9.5%) occurred with a catheter in the femoral vein ( Table 3) . Patients of Group 2 suffered from a higher incidence of VTE than Group 1 (65% vs 13.6%, p=0.001). Proximal DVT J o u r n a l P r e -p r o o f Journal Pre-proof occurred in 13 patients (30.9%). Three symptomatic patients (7.1%) showed segmental pulmonary embolisms (1 of Group 1 and 2 of Group 2) ( Table 3) . Based on risk factors (i.e. D-dimer), our observational study suggests that, the severe form of COVID-19 infection in critically ill patients has a clear pattern of inflammation and hypercoagulability with progression to organ failure, worsening the outcome in term of mortality and length of ICU stay. Our results showed an ICU mortality rate of 25% and it was likely determined by the different categorization of patients based on risk factors. According to recent evidences [9;15] , we stratified patients on D-dimer value (high risk with D-dimer ≥3.000 ng/mL and low risk with D-dimer <3.000 ng/mL). Patients identified as high risk had more comorbidities, including increased rates of obesity and inflammation (high IL-6) compared to low risk patients. Moreover, they had significantly higher lengths of stay in both the ICU and hospital than low risk patients (11.5 ± 5.6 vs 9.0 ± 4.8 and 30±4.9 vs 21±2.3, p<0.05, respectively). Heparins seems to have a biological basis as a modulator of inflammation through four ways: 1. inhibits the activation of neutrophils; 2. interacts with the vascular endothelium to prevent expression of inflammatory mediators which initiate and drive activation of the immune system; 3. inhibits proliferation of the vascular smooth muscle cells; 4. inhibits inflammation via its anticoagulant activity: a fall in thrombin formation in turn reduces adhesion molecules as well as platelet activation [22] . In the literature there are no high-quality data yet supporting early use of LMWH at a therapeutic dose in patients with COVID-19, outside the setting of VTE treatment; randomized controlled studies evaluating this question are planned [23] or open to recruitment (NCT04362085, NCT04345848, NCT04359277) or performed in a low number of patients [24] . In a French study conducted by Llitjos et al. [24] in which there were included 26 critically ill patients with severe COVID-19 pneumonia, the anticoagulation dose (prophylactic or therapeutic) was chosen at the discretion of the treating physician based on the individual risk of thrombosis; the authors found no difference within groups, suggesting that therapeutic dose could be unjustified. Moreover, in our study, in patients with D-dimer less than 3.000, in which we administered to all patients an intermediate dose of heparin, we found a mortality rate lower than in patients treated with prophylactic dose of French study (9.1% vs 12%). Similar to our study, Tang et al [9] stratified patients based on D-dimer value. They found a higher mortality rate in heparin users than our patient population (32.8% vs J o u r n a l P r e -p r o o f Journal Pre-proof 25%) for severe COVID-19 patients with a D-dimer >3.000 ng/mL. However, the authors had used heparin treatment with a prophylactic dose. The overall incidence of venous thromboembolic events (perivascular thrombosis, DVT and PE) was considerable in our patient population (38%); moreover, it was statistically significantly higher in patients of Group 2 compared to Group 1. The total incidence of PE was 7.1%. These results are different from those of a recent study in 184 ICU patients that reported an ultrasonography VTE in 27% of patients; moreover, PE was the most frequent thrombotic complication (81%) [3] . The higher mortality in our population than in the literature [15; 24] could be linked to the presence of microvascular thrombosis which cannot be diagnosed with instrumental investigations. An anatomic study [25] documented that at least some COVID-19 patients who become critically ill suffer a generalized thrombotic microvascular injury. Such pathology involves the lungs and appears mediated by intense complement activation. Despite the use of therapeutic anticoagulation, no major hemorrhagic events, and no sign of SIC occurred; this highlights the possible safety even of high dose anticoagulant in these patients where the thromboembolic risk may exceed the bleeding risk. In conclusion, risk stratification based on D-dimer values is fundamental in critically ill patients with COVID-19: high-risk patients are more severe with an hyperinflammation state, have higher incidence of thromboembolic events and worse outcome compared with low risk ones. This aspect may have justified the use of heparin in therapeutic doses which however, did not lead, at least in our patient population, to an increase of bleeding risk. It seems appropriate to underline some limitations: first, this is a single center study and the data on the influence over time of anticoagulant therapy on pro-inflammatory cytokines and fibrinolysis parameters, is missing. Second, it is not possible to draw definitive and certain conclusions about the efficacy of a high dose of LMWH on outcomes because the studied groups had a different severity of illness. Third, we decided to not include patients admitted to the ICU with COVID-19 and treated with VKA or DOAC due to the interference on the monitoring of coagulation parameters on ICU admission. Coronaviruses and the cardiovascular system: acute and long-term implications Hypothesis for potential pathogenesis of SARS-CoV-2 infection: a review of immune changes in patients with viral pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Low anticoagulant heparin blocks thrombininduced endothelial permeability in a PAR-dependent manner The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Surviving sepsis campaign: international guidelines for management of sepsis and septic shock Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance 28 ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia KDIGO Clinical Practice Guideline for Acute Kidney Injury Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring Evaluation of pre-clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized study More than an anticoagulant: do heparins have direct anti-inflammatory effects? Randomized controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases The authors want to thank all the medical team, nursing, and paramedics staff of the Intensive Care Unit of Santa Maria Annunziata Hospital (Bagno a Ripoli, Italy), who made it possible to treat patients in this pandemic. The authors are also grateful to Dr. Andrew Horton (School of Dentistry University of Utah Health, Salt Lake City, USA) for his invaluable assistance in manuscript editing. None to declare.